Search by Drug Name or NDC
NDC 00024-5824-11 Jevtana Details
Jevtana
Jevtana is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sanofi-Aventis U.S. LLC. The primary component is .
MedlinePlus Drug Summary
Cabazitaxel injection is used along with prednisone to treat prostate cancer (cancer of a male reproductive organ) that has already been treated with other medications. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of cancer cells.
Related Packages: 00024-5824-11Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Cabazitaxel Injection
Product Information
| NDC | 00024-5824 |
|---|---|
| Product ID | 0024-5824_a2143f39-0543-4e3d-bba8-4d21f4bb5efb |
| Associated GPIs | 21500003002020 |
| GCN Sequence Number | 066476 |
| GCN Sequence Number Description | cabazitaxel VIAL FDN10MG/ML INTRAVEN |
| HIC3 | V1F |
| HIC3 Description | ANTINEOPLASTICS,MISCELLANEOUS |
| GCN | 28762 |
| HICL Sequence Number | 037047 |
| HICL Sequence Number Description | CABAZITAXEL |
| Brand/Generic | Brand |
| Proprietary Name | Jevtana |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | cabazitaxel |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | KIT |
| Route | n/a |
| Active Ingredient Strength | n/a |
| Active Ingredient Units | n/a |
| Substance Name | n/a |
| Labeler Name | Sanofi-Aventis U.S. LLC |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA201023 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00024-5824-11 (00024582411)
| NDC Package Code | 0024-5824-11 |
|---|---|
| Billing NDC | 00024582411 |
| Package | 1 KIT in 1 CARTON (0024-5824-11) * 5.7 mL in 1 VIAL, GLASS (0024-5822-01) * 5.7 mL in 1 VIAL, GLASS (0024-5823-15) |
| Marketing Start Date | 2010-06-17 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |